Abilify Maintena Injection
PDF Leaflet Revision Date: 5 March 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Maintenance treatment of schizophrenia in adults stabilized with oral aripiprazole.
Dosage (summary)
Starting dose: 400 mg once monthly; may reduce to 300 mg if adverse reactions occur.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not established in pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- Strong CYP2D6 inhibitors
- Strong CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to aripiprazole or excipients
Common side effects
- Weight increased
- Akathisia
- Insomnia
- Injection site pain
Counselling Points
- Monitor for signs of hyperglycemia
- Avoid abrupt discontinuation
- Report any new or increased urges for gambling or other compulsive behaviors
Serious warnings
- Increased mortality in elderly with dementia-related psychosis
- Risk of suicidality
- Neuroleptic malignant syndrome
Important Disclaimer
The Abilify Maintena Injection professional information leaflet below is the property of H Lundbeck and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
